Global Shingles Treatment Market, By Treatment (Medication and Vaccinations), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Shingles Treatment Market Analysis and Size
According to the CDC, about one out of three individuals in the U.S. will develop shingles. Vaccination is recommended in several major countries, such as the U.S., Canada, the U.K., Italy, Australia, New Zealand, Germany, and South Korea. In March 2021, the CDC released guidelines associated with shingles vaccination during the COVID-19 pandemic and designated it as an essential preventive care service. Shingles are most normal in individuals who are beyond 50 years old. The infection may return in individuals of any age who have had chickenpox beforehand.
Data Bridge Market Research analyses a growth rate in the shingles treatment market in the forecast period 2023-2030. The expected CAGR of the shingles treatment market tends to be around 8.00% in the mentioned forecast period. The market was valued at USD 124.26 million in 2022, and it would grow up to USD 230 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Shingles Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Medication and Vaccinations), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), GSK plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Takeda Pharmaceutical Company Limited (Japan), BIO-MED (India), Intercept Pharmaceuticals, Inc (U.K.), Emcure Pharmaceuticals Limited(India), Changchun BCHT Biotechnology Co. (China), Novo Medi Sciences (India)
|
|
Market Opportunities
|
|
Market Definition
Shingle is a type of viral infection that causes a painful rash on the back. Although the rashes of shingles can occur anywhere on the body majorly, they are found on the right and left side of the torso with single-strip as appearance. It is caused by the varicella-zoster virus — the same virus that causes chickenpox or varicella. After chickenpox, the virus is inactive in nerve tissue near the spinal cord and brain. After many years, the virus may reactivate as shingles.
Global Shingles Treatment Market Dynamics
Drivers
- Increasing Awareness about Vaccination
The U.S. Advisory Committee on Immunization Practices has recommended vaccination against shingles in adults aged 60 years and above since 2006. In January 2018, the CDC recommended Shingrix over Zostavax to prevent Shingles due to the high efficacy of the vaccine. Likewise, Canada, Australia, and some European countries also recommend vaccination to decrease the disease burden. Thus, all these activities boost the growth of the market.
- Growing Cases of Herpes Zoster
The growing cases of herpes zoster worldwide are projected to increase vaccine uptake in the coming years. The prevalence of herpes zoster is expected from 3 to 5 per 1,000 individuals per year, and it increases with age. According to a study conducted in Germany, the estimated annual zoster incidence is 5.79 cases per 1,000 population. The high risk of herpes zoster is projected to increase the adoption of shingles vaccines. This boost the growth of the market.
Opportunities
- Increased Immunization Programs
The inclusion of shingles vaccines in national immunization programs of numerous countries is estimated to boost the market growth. For instance, in Australia, vaccination against shingles is funded under the National Immunization Program for adults aged 70 to 79 years, as people in this age group have a higher risk of developing herpes zoster and are estimated to benefit the most from vaccination. Likewise, other countries such as the U.S., the U.K., and Italy have included shingles vaccination in their national immunization programs to decrease the disease burden. Thus, all these immunization programs create many opportunities for market growth.
- Increase in Elderly Population
According to the National Institute on Aging reports, about 524 million individuals were above the age of 65 in 2010. This number is projected to rise and reach up to 1.5 billion, which is nearly 16% of the global population, by 2050. This boost the market growth
Restraints/Challenges
- High Cost of Treatment
The medical cost of herpes zoster is rising yearly with the increasing disease incidence worldwide. The current treatments can only shorten the duration and decrease symptoms. Several government regulatory bodies recommend vaccination against this disease to reduce the healthcare system's treatment cost burden and shingles' occurrence.
- Unavailability of Vaccinations
There is huge unavailability of vaccines that is hindering the market growth. Vaccination for shingles is not available in many regions. And thus, it gets the population out there to deal with the outbreak. Thus, in a way, it hampers the market growth.
This global shingles treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global shingles treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development:
- In July 2021, GlaxoSmithKline plc. received FDA approval for Shingrix vaccines in adults aged 18. The vaccine is approved for people who are or will be at higher risk for immunosuppression and immunodeficiency.
Global Shingles Treatment Market Scope
The global shingles treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Vaccinations
Route of Administration
- Oral
- Topical
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Shingles Treatment Market Regional Analysis/Insights
The global shingles treatment market is analyzed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global shingles treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing positive growth for the global shingles treatment market throughout the forecast period due to the presence of major key players and the increased prevalence of chickenpox and shingles.
Asia-Pacific dominates the market due to the increased prevalence of shingles infection and easily availability of drugs in the region
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Shingles Treatment Market Share Analysis
The global shingles treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global shingles treatment market
Key players operating in the global shingles treatment market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- GSK plc (U.K.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- BIO-MED (India)
- Intercept Pharmaceuticals, Inc (U.K.)
- Emcure Pharmaceuticals Limited(India)
- Changchun BCHT Biotechnology Co. (China)
- Novo Medi Sciences (India)
Research Methodology: Global Shingles Treatment Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-